ClinicalTrials.gg
Not yet recruitingNCT07856264Updated Oct 2, 2026

PCSK9 Inhibitors in Hyperlipidemia and Atherosclerosis

An observational study in Hyperlipidemia and Atherosclerotic Cardiovascular Disease (ASCVD), sponsored by Fundación Santa Fe de Bogota. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Fundación Santa Fe de Bogota · Observational

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

PCSK9 inhibitors, including evolocumab and alirocumab, are lipid-lowering therapies used in patients with hyperlipidemia and atherosclerotic cardiovascular disease. This retrospective observational study aims to describe changes in low-density lipoprotein cholesterol (LDL-C) levels following the use of PCSK9 inhibitors in adult patients with hyperlipidemia and/or atherosclerotic cardiovascular disease treated at Fundación Santa Fe de Bogotá between 2018 and 2024. The study will also describe patients' clinical characteristics, treatment effectiveness, safety, adherence, and barriers to treatment access. Data will be obtained from medical records, cardiology records, and telephone interviews when needed to complete missing information.

02

Conditions studied

  • Hyperlipidemia
  • Atherosclerotic Cardiovascular Disease (ASCVD)
03

In context

Hyperlipidemias

864 studies on the registry are indexed under Hyperlipidemias; 110 are open to participants now.

This study's planned enrollment of 100 is below the median of 335 across 102 observational studies indexed under Hyperlipidemias.

Browse Hyperlipidemias studies →

Lead sponsor

Fundación Santa Fe de Bogota is the lead sponsor of 27 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients over 18 years of age with hyperlipidemia and/or atherosclerotic heart disease in Bogotá.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older with a clinical diagnosis of hyperlipidemia and/or atherosclerotic cardiovascular disease (ASCVD) according to ESC/EAS guidelines who also meet the following criteria:

Patients who initiated treatment with evolocumab or alirocumab between 2018 and 2024.

Patients who received at least one dose of evolocumab or alirocumab. Patients followed by the Cardiology Department at Fundación Santa Fe de Bogotá. Patients with at least one measured and/or calculated low-density lipoprotein cholesterol (LDL-C) level within the 6 months prior to initiation of evolocumab or alirocumab.

Exclusion criteria

Exclusion Criteria:

  • Patients with prior exposure to PCSK9 inhibitor therapy within the 6 months before initiation of evolocumab or alirocumab.

Patients without at least one LDL-C measurement after initiation of PCSK9 inhibitor therapy.

Patients without at least one LDL-C measurement within the 6 months prior to initiation of evolocumab or alirocumab.

Patients with incomplete medical records from which identification or contact information cannot be obtained.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in low-density lipoprotein cholesterol (LDL-C) levels

    Change in low-density lipoprotein cholesterol (LDL-C) levels following treatment with evolocumab or alirocumab in patients with hyperlipidemia and/or atherosclerotic cardiovascular disease (ASCVD) during the study period.

    Time frame: January-2018 to July-2024

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2027; primary completion for Jul 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartEst.
Feb 1, 2027
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856264
Lead sponsor
Fundación Santa Fe de Bogota
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 2, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion